Trends
Eli Lilly's top drug last year is softening. But it may not matter for the stock
Analysts see weak trends for Trulicity, which led all Eli Lilly drugs in sales last year. But that won't keep the stock from going higher.
Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. But that might not be enough to stop its stock from climbing higher. Prescription data for multiple Eli Lilly dr... [4880 chars]
Related
Share this page
Guest Posts by Easy Branches
